H. Lundbeck A/S (HLUBF)
8.35
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
H. Lundbeck Shareholders Equity (Quarterly) : 4.293B for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 4.293B |
| June 30, 2026 | 4.109B |
| March 31, 2026 | 3.951B |
| December 31, 2025 | 3.916B |
| September 30, 2025 | 3.959B |
| June 30, 2025 | 3.806B |
| March 31, 2025 | 3.558B |
| December 31, 2024 | 3.473B |
| September 30, 2024 | 3.569B |
| June 30, 2024 | 3.337B |
| March 31, 2024 | 3.248B |
| December 31, 2023 | 3.267B |
| September 30, 2023 | 3.167B |
| June 30, 2023 | 3.161B |
| March 31, 2023 | 3.060B |
| December 31, 2022 | 2.982B |
| September 30, 2022 | 2.756B |
| June 30, 2022 | 2.755B |
| March 31, 2022 | 2.759B |
| December 31, 2021 | 2.795B |
| September 30, 2021 | 2.818B |
| June 30, 2021 | 2.797B |
| March 31, 2021 | 2.722B |
| December 31, 2020 | 2.790B |
| September 30, 2020 | 2.635B |
| Date | Value |
|---|---|
| June 30, 2020 | 2.502B |
| March 31, 2020 | 2.388B |
| December 31, 2019 | 2.521B |
| September 30, 2019 | 2.098B |
| June 30, 2019 | 2.060B |
| March 31, 2019 | 1.913B |
| December 31, 2018 | 2.183B |
| September 30, 2018 | 2.108B |
| June 30, 2018 | 1.968B |
| March 31, 2018 | 1.919B |
| December 31, 2017 | 1.965B |
| September 30, 2017 | 1.834B |
| June 30, 2017 | 1.641B |
| March 31, 2017 | 1.413B |
| December 31, 2016 | 1.375B |
| September 30, 2016 | 1.382B |
| June 30, 2016 | 1.323B |
| March 31, 2016 | 1.336B |
| December 31, 2015 | 1.279B |
| September 30, 2015 | 1.346B |
| June 30, 2015 | 1.521B |
| March 31, 2015 | 2.057B |
| December 31, 2014 | 2.198B |
| September 30, 2014 | 2.369B |
| June 30, 2014 | 2.462B |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Novo Nordisk A/S | 33.09B |
| ALK-Abello A/S | 1.062B |
| AstraZeneca PLC | 47.33B |
| ANI Pharmaceuticals, Inc. | 637.11M |
| Corcept Therapeutics, Inc. | 833.74M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 8.181B |
| Total Liabilities (Quarterly) | 3.889B |
| Debt to Equity Ratio | 0.3065 |
| Current Ratio | 1.429 |
| Net Debt Paydown Yield | 2.62% |